BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 32957579)

  • 1. Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study.
    Lotfinejad P; Asghari Jafarabadi M; Abdoli Shadbad M; Kazemi T; Pashazadeh F; Sandoghchian Shotorbani S; Jadidi Niaragh F; Baghbanzadeh A; Vahed N; Silvestris N; Baradaran B
    Diagnostics (Basel); 2020 Sep; 10(9):. PubMed ID: 32957579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
    Gao G; Wang Z; Qu X; Zhang Z
    BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL) and programmed death ligand 1 (PD-L1) expression in gastric cancer: a systematic review and meta-analysis.
    Ren J; He Q; Yin H; Zheng L; Li L; Wu X
    Clin Transl Oncol; 2023 May; 25(5):1436-1445. PubMed ID: 36528835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
    Wang X; Liu Y
    Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.
    Huang W; Ran R; Shao B; Li H
    Breast Cancer Res Treat; 2019 Nov; 178(1):17-33. PubMed ID: 31359214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
    Zhang L; Wang XI; Ding J; Sun Q; Zhang S
    Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of different PD-L1 expression patterns and tumor-infiltrating lymphocytes in high-grade serous ovarian cancer: a systematic review and meta-analysis.
    Wang YM; Cai W; Xue QM; Zhang JY; Zhou L; Xiong SY; Deng H
    Front Immunol; 2023; 14():1234894. PubMed ID: 37654479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.
    Noske A; Möbus V; Weber K; Schmatloch S; Weichert W; Köhne CH; Solbach C; Ingold Heppner B; Steiger K; Müller V; Fasching P; Karn T; van Mackelenbergh M; Marmé F; Schmitt WD; Schem C; Stickeler E; Loibl S; Denkert C
    Eur J Cancer; 2019 Jun; 114():76-88. PubMed ID: 31075727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
    Uğurluoğlu C; Yormaz S
    Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
    Zhang C; Yang Q
    Front Oncol; 2020; 10():572203. PubMed ID: 33634012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
    Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM
    Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569
    [No Abstract]   [Full Text] [Related]  

  • 14. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
    Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
    Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M
    Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis.
    Li S; Chen L; Jiang J
    Medicine (Baltimore); 2019 Apr; 98(16):e15201. PubMed ID: 31008945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients.
    AiErken N; Shi HJ; Zhou Y; Shao N; Zhang J; Shi Y; Yuan ZY; Lin Y
    Int J Biol Sci; 2017; 13(9):1172-1179. PubMed ID: 29104508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis-related novel immunostaining pattern for programmed cell death ligand 1 and prognostic value of tumour-infiltrating lymphocytes in triple-negative breast cancer.
    Savaş P; Serin G; Gürsoy P; Zekioğlu O; Özdemir N
    Pol J Pathol; 2023; 74(2):65-74. PubMed ID: 37728465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.
    Li X; Wetherilt CS; Krishnamurti U; Yang J; Ma Y; Styblo TM; Meisel JL; Peng L; Siddiqui MT; Cohen C; Aneja R
    Am J Clin Pathol; 2016 Oct; 146(4):496-502. PubMed ID: 27686176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.